Market Overview

UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts

Related BMY
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?
FDA declines expanded approval for Bristol-Myers oncology drug (Seeking Alpha)

In a report published Monday, J.P. Morgan analyst Chris Schott upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Neutral to Overweight, and raised the price target from $50.00 to $52.00.

In the report, J.P. Morgan noted, “With Bristol shares having pulled back over the past several months, we are upgrading the stock to Overweight ahead of a number of important catalysts over the next 12-18 months, particularly for the company's immunotherapy platform. These include initial nivolumab/Yervoy combo data in NSLSC as well as the completion of several nivolumab phase III studies. While Bristol trades at a high multiple on near-term earnings (21x 2014E), we forecast a roughly 13% EPS CAGR for the company through 2020 with substantial potential upside to these estimates as we get additional clarity on the company's pipeline.”

Bristol-Myers Squibb Co. closed on Friday at $43.56.

Latest Ratings for BMY

Sep 2015UBSUpgradesNeutralBuy
Aug 2015JefferiesMaintainsHold
Aug 2015Piper JaffrayUpgradesUnderN

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Chris Schott J.P. MorganAnalyst Color Upgrades Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters